Mouse Genome Informatics
ht
    Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * C57BL/6
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
       
mortality/aging
• 28% of mutants die by 17 months of age due to tumors (J:17728)
• heterozygous mutants die between 150 to 750 days after birth (J:95318)

tumorigenesis
• tumors show loss of heterozygosity for Trp53
• age of onset 9 months
• 5.9% incidence
• 25% of mutants exhibit lymphomas (J:17728)
• 32% incidence (J:72391)
• 32% of heterozygous mutants developed lymphomas (J:95318)
• 35% incidence of carcinomas (J:72391)
• 2.9% incidence of pancreatic adenocarcinomas (J:72391)
• 12% of heterozygous mutants developed carcinomas, which are rare in homozygotes (J:95318)
• 18% incidence of ear squamous cell carcinoma
• 57% of mutants exhibit sarcomas (J:17728)
• 56% incidence of sarcomas (J:72391)
• 2.9% incidence of undifferentiated sarcomas (J:72391)
• 56% of heterozygous mutants developed sarcomas (J:95318)
• 8.8% incidence (J:72391)
• 29% incidence (J:72391)
• 2.9% incidence of pancreatic adenocarcinomas

digestive/alimentary system
• 2.9% incidence of small intestinal polyps
• 2.9% incidence of stomach polyps

Mouse Models of Human Disease
OMIM IDRef(s)
Li-Fraumeni Syndrome 1; LFS1 151623 J:17728